Show results for
Refine by
Locations
- Europe
- Albania
- Andorra
- Austria
- Belarus
- Belgium
- Bosnia & Herzegovina
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Faroe Islands
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Kosovo
- Latvia
- Liechtenstein
- Lithuania
- Luxembourg
- Macedonia
- Malta
- Moldova
- Monaco
- Montenegro
- Netherlands
- Northern Ireland
- Norway
- Poland
- Portugal
- Romania
- San Marino
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
- Vatican City
Mitral Regurgitation Equipment Supplied In Europe
4 equipment items found
by:Cardiac Dimensions, Inc. based inKirkland, WASHINGTON (USA)
A completely different and much earlier approach to treating functional mitral regurgitation (FMR) than any other device therapy currently available to patients. The goal: Treat the condition—not just the symptoms. The Carillon System is designed to work with the natural structure and function of the heart to help treat the condition of FMR as well as the ...
Manufactured by:Edwards Lifesciences Corporation based inIrvine, CALIFORNIA (USA)
In the early days of transcatheter mitral valve repair, the goal was a successful procedure that reduced mitral regurgitation (MR) to less than 3+; residual MR grade 2+ was considered acceptable.1,2 Compelling new data on more than 5400 patients show that residual MR grades 0–1+ are significantly associated with superior patient outcomes ...
by:InnovHeart Srl. based inMilano, ITALY
The Mitral Valve is a complex structure positioned between the left atrium and the left ventricle. Its function is to make unidirectional the blood flow from the left atrium to the left ventricle. The Mitral Valve can be affected by two major dysfunctions: Mitral Valve Stenosis (i.e. narrowing of the mitral valve orifice), and ...
Manufactured by:Shockwave Medical Inc. based inSanta Clara, CALIFORNIA (USA)
Neovasc is focused on creating better outcomes for difficult-to-treat cardiology patients through the development of two novel products: Reducer™* for treatment of refractory angina and the Tiara™ System* for treatment of mitral valve regurgitation. Millions of patients worldwide with coronary artery disease who are not candidates for ...